Tel +44 (0)23 8120 5170, Fax +44 (0)23 8120 5152 * Joint first authors Abstract Objective To investigate perturbations in downstream signalling pathway activation and potential resistance mechanisms to EGFR and/or HER2 inhibition in cell line models of bladder cancer.
Transitional cell carcinoma (TCC) of the bladder accounts for 10,000 new diagnoses and 5,000 deaths annually in the UK. Cisplatin based combination chemotherapy, in those fit enough to receive it, is the standard of care for initial systemic therapy. This results in a median survival of approximately 14 months as palliative treatment for metastatic TCC or an absolute survival advantage of 5-6% in the neoadjuvant setting prior to radical cystectomy or radiotherapy. 1 Immunotherapy has recently been demonstrated to be effective as a second line palliative treatment but the disease is rapidly lethal in these circumstances with a median survival of only 10 months. 2 Furthermore, no molecularly targeted or stratified treatment strategy has yet been established for this disease. A significant unmet need therefore exists to develop new therapeutic approaches based on underlying disease biology. 1 The human epidermal growth factor receptor (HER) family are cell surface tyrosine kinase receptors which include the epidermal growth factor receptor (EGFR), HER2, HER3 and HER4. Cognate ligand binding induces homo-or hetero-dimerisation between HER family members followed by diverse downstream signalling pathway activation. Although their oncogenic activity is believed to be mediated primarily through the RAS/mitogen activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways, other pathways may also be involved including the signal transducer and activator of transcription (STAT) and phospholipase C and SRC/FAK pathways. Aberrant HER family activation in various cancers induces cellular proliferation, migration, attenuation of apoptosis, invasion and metastasis.
EGFR and/or HER2 are established as clinical therapeutic targets for breast cancer, gastric cancer, non-small cell lung cancer, head and neck cancer and colorectal cancer. 1, 3 Page 3 of 23 EGFR and HER2 protein over-expression in TCC/bladder cancer is poorly defined at between 35-96% and 8-98% respectively. 4-9 Increased expression of either has been linked to TCC grade, stage and survival outcomes. 4-6, 8-11 Prognostic impact of EGFR and HER2 expression may link to their co-expression status with respect to each other and also with HER3 and HER4. 7, 11 EGFR and/or HER2 inhibition have been demonstrated to be active in pre-clinical models and have been tested in early phase TCC clinical trials, either as single agents, or in combination with cytotoxic chemotherapy. 1, 3, [12] [13] [14] [15] Single agent clinical activity in response to targeted inhibition of either EGFR or HER2 is established but randomised data and clear demonstration of efficacy that would warrant routine use is awaited. Furthermore the requirement for a patient selection strategy and how this should be undertaken are currently unknown.
Understanding of factors linked to response to EGFR and/or HER2 inhibition in TCC will likely be critical to patient selection for these approaches and may elucidate strategies for future clinical evaluation. We hypothesised that interrogation of downstream signalling pathway activation following chemical inhibition of EGFR and/or HER2 would allow for identification of critical molecular 'nodes' relevant for therapeutic efficacy. We demonstrate that p38 mitogen-activated protein kinase (MAPK) is activated in response to EGFR/HER2 inhibition in pre-clinical models for TCC/bladder cancer and that it represents a potential new therapeutic target.
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Cell proliferation was measured as previously described using CellTiter 96 AQueous One Solution Reagent (Promega, Southampton, UK) or by using the CellTiter-Glo® 2.0 assay (Promega, Southampton, UK) according to the manufacturer's instructions. 18 
Human phosphokinase array
A human phospho-kinase membrane-based sandwich immunoassay (Proteome Profiler Human Phospho-Kinase Array Kit ARY003, R&D Systems, Abingdon, UK) was used to detect simultaneously the relative phosphorylation levels of 46 protein kinase phosphorylation sites of potentially relevant signalling pathways downstream of EGFR and/orHER2. 3x10 6 cells were cultured overnight before treating for one Page 6 of 23 hour with the relevant drug or DMSO solvent control. Following EGFR and/or HER2 inhibition the array was processed according to the manufacturer's protocol.
Phosphorylated protein was detected using ECL reagent on a ChemiDoc-It Imaging
System (Ultra-Violet Products, UK) using VisionWorksLS Image Acquisition and Analysis software (UVP Ltd).
Phosphokinase array data analysis
Signals from the phosphokinase array were quantified using Quantity One software. Data were then analysed by each of three different methods: i) as raw data (pixel density), ii) as a percentage of the array positive control mean signal, and iii) as a percentage of the global mean of all signals on the array. Only phosphokinase changes that reached statistical significance (p<0.05) by each of these three analysis approaches were taken forward for subsequent investigation and validation.
Statistical analysis was performed using Student's t-test and presented for p values
<0.01 and <0.05.
Results

Erlotinib and lapatinib response in bladder cancer cell lines
Mechanisms for resistance to inhibition of EGFR and/or HER2 might include alterations to downstream signalling pathway activation. To investigate this hypothesis in bladder cancer cell lines we undertook an initial screen to assess activation, in terms of kinase phosphorylation status, through a phosphokinase array.
We utilised prospectively determined criteria for subsequent selection and validation of altered downstream signalling pathway nodes (Additional file 1: Figure S1 ). Our approach was to incorporate both the EGFR inhibitor erlotinib and the dual EGFR/HER2 inhibitor lapatinib with the intention to detect downstream signalling impacts that were common to both drugs. RT112 cells were chosen for initial analyses, as they expressed relatively high levels of both EGFR and HER2 amongst a panel of bladder cancer cell lines assessed ( Fig. 1A) and were sensitive to both erlotinib (IC 50 6.6 µM) and lapatinib (IC 50 6.1 µM) in cell proliferation experiments. In this cell line, downregulation of phospho-ERK1/2 was robust following exposure to the EGFR inhibitor erlotinib by 1 hour (Fig. 1B ) and we therefore selected this time point for initial studies.
1st phosphokinase array screen of erlotinib treatment of RT112 cells
The phosphokinase array was used to interrogate RT112 cells after treatment with erlotinib for 1 hour at a dose of 5 times the IC 50 value determined in cell proliferation experiments (data not shown). Increased expression was seen for 9 phospho-protein targets in erlotinib treated compared to control cells ( Fig. 1C and Additional file 1: Figure S2 and S3), with consistent results achieved with each of the three data analysis methods used (Additional file 1: Figure S4A , B). These were p38 MAPK (Thr180/Tyr182), GSK-3α/β (Ser21/9), MEK1/2 (Ser218/222, Ser222/226), Akt (Ser473), TOR (Ser2448), Src (Tyr419), p27 (Thr198), p27 (Thr157) and PLCγ-1 (Tyr783). In addition STAT4 (Tyr693) phosphorylation was reduced. Discrepancy was seen with the phosphorylation status of p53 (Ser392) (upregulated when analysed by pixel density, but downregulated when analysed by the percentage of the positive control or percentage of the global mean of signals) and so it was excluded, based on our pre-determined analysis plan, from subsequent validation steps.
Validation step 1 (2 nd phosphokinase array) of lapatinib treatment of RT112 cells
We next undertook a validation step by retesting only the 10 phosphokinase targets confirmed to change on exposure to erlotinib by undertaking a second phosphokinase array experiment in RT112 cells but with the dual EGFR/HER2 inhibitor lapatinib, again at 5 times its IC 50 concentration for cell proliferation. In doing so, we validated 3 of the 10 phospho-proteins assessed that were again found to alter in their expression status. These were p38 MAPK (Thr180/Tyr182) and GSK-3α/β (Ser21/9) which were upregulated and STAT4 (Tyr693) which was downregulated ( Fig. 1D and Additional file 1: Figure S4c , 4d, S5 and S6).
Validation step 2, individual phosphokinase experiments
To further validate the two rounds of phosphokinase array results, we undertook Western blot analyses for phosphorylation status of p38 MAPK (Thr180/Tyr182), GSK-3α/β (Ser21/9) and STAT4 (Tyr693) in response to erlotinib or lapatinib exposure. We found consistent increases in phosphorylation of p38 MAPK in Page 9 of 23 response to either drug ( Fig. 2A, B ). However, no difference was confirmed in the phosphorylation status of GSK-3α/β or STAT4 (data not shown). The increase of p38 MAPK phosphorylation in response to inhibition of EGFR or EGFR/HER2 was confirmed both in RT112 cells and also in T24 bladder cancer cells ( Fig. 2A, B , C, D).
We then extended the validation of our findings by replicating the impact on p38 phosphorylation in response to either EGFR or HER2 depletion by siRNA in RT112 cells ( Fig. 2E ). Depletion of either receptor increased p38 phosphorylation.
Combination inhibition of p38 MAPK and EGFR +/-HER2 in bladder cancer cell lines
We hypothesised that p38 MAPK phosphorylation in response to EGFR and/or HER2 inhibition could represent an escape mechanism to EGFR/HER2 directed therapy and represent a therapeutic target in bladder cancer cells. We first tested chemical inhibition of p38 MAPK with the pyridinyl imidazole compound SB203580 and found an anti-proliferative effect in UM-UC-3, RT112 and T24 cell lines with mean IC 50 values of 76.78 µM, 20.85 µM and 79.12 µM respectively (Fig 3) .). Next we tested the effect, in UM-UC-3, T24 and RT112 cells, of dual EGFR/HER2 inhibition using lapatinib in combination with p38 MAPK inhibition with SB203580.
Cell growth inhibition when these drugs were combined was greater than the effect with either drug alone (Fig. 4A ) in all cell lines tested and these differences were statistically significant (p<0.0001). Similar effects were seen when combining EGFR inhibition with erlotinib and SB203580 in all cell lines analysed (Fig. 4B) Next we undertook fractional effect analyses to formally test for a synergistic interaction between lapatinib and SB203580 in RT112 cells ( Fig. 4C) . Of the dose combinations tested, if both drugs were each combined at 0.75 times their respective IC 50 values or greater, then we achieved ~100% cell growth inhibition. The calculated combination index (CI) values, where values <1 indicate 'synergy', at IC 50 , IC 75 and IC 90 were 0.66, 0.59 and 0.53 respectively. Similar interactions with combination therapy were seen in T24 cells (Fig. 4D) . The calculated CI values at ED50, ED75 and ED90 were 0.64, 0.53 and 0.45 respectively.
Discussion
Chemotherapy remains the standard of care for the systemic therapy of muscle invasive bladder cancer but outcomes are modest. We have yet to see any molecularly targeted therapeutic strategies introduced for this disease and so a significant unmet clinical need remains. 1 EGFR and HER2 are amongst the more promising therapeutic targets currently under clinical development in bladder cancer.
However it remains unclear what the most appropriate selection strategy or the potential mechanisms of resistance to this approach might be. We took chemical inhibition of EGFR or EGFR/HER2, using agents currently in clinical evaluation for bladder cancer, as a starting point for a screen/validation approach to detect downstream signalling targets of potential therapeutic importance. Using this approach, we have identified p38 MAPK as a consistently activated downstream signalling node and were able to validate this across cell lines and with multiple approaches to EGFR and/or HER2 inhibition.
p38 MAPK belongs to a family which also includes ERK1/2 (extracellular signalregulated kinases 1 and 2) and JNKs (c-Jun-N-terminal kinases). 19 p38 MAPK exists as four isoforms (α, β, γ and δ) encoded by different genes. p38α is expressed at high levels in most cell types whereas p38β is expressed at lower levels and expression of the other two members, p38γ and p38δ, is tissue-specific. 20 Extracellular signals activate the MAPK cascade to phosphorylate p38α in threonine and tyrosine residues, resulting in a kinase activating conformational change. 20 Activated p38α phosphorylates multiple cellular targets, including DNA and RNAbinding proteins involved in the regulation of gene expression, transcription factors (e.g., ATF2, MEF2A, SAP1, CHOP, Elk-1, STAT1, STAT4 and p53) serine and threonine kinases (e.g., GSK-3β, MK2, MK3, MSK1 and MSK2) and regulatory proteins involved in cell cycle regulation (e.g., cyclin D1, cyclin D3 and p57kip2) apoptosis (e.g., Bax and BimEL) and cell survival (e.g., caspase-3 and caspase-8). 20 p38 MAPK impacts on diverse cellular functions including immune and inflammatory responses, the cell cycle, cellular proliferation, apoptosis and acts as a tumour suppressor. [21] [22] [23] The potential role of p38 MAPK in bladder cancer is poorly defined to date and has received little investigation. In a study of 91 primary bladder cancer samples p38 MAPK expression was associated with higher tumour grade and detrusor muscle invasion 24 . In preclinical models, p38 MAPK was shown to regulate invasion of bladder cancer cells by modulating matrix metalloproteinases 2 and 9. 25 Additionally, p38 MAPK activation may confer resistance to apoptosis and a survival advantage to bladder cancer cells. 26 Our screening approach to determine the impact of EGFR and/or HER2 chemical inhibition on downstream signalling detected consistent p38 MAPK phosphorylation in RT112 and T24 bladder cancer cells. We were then able to validate these findings by siRNA depletion of EGFR or HER2. This is in accordance with findings in glioblastoma multiforme cells after treating with the dual EGFR and HER2 inhibitor GW2974. 27 Further investigation through combination treatment experiments including fractional effect assays showed that dual EGFR/HER2 inhibition with lapatinib combined with the p38 MAPK inhibitor SB203580 had a synergistic effect on cell proliferation inhibition in UM-UC-3, RT112 and T24 cells. A possible explanation for synergism would be that lapatinib inhibits the activation of Ras-MAPK and PI3K/Akt pathways, leading to cell cycle arrest and apoptosis, but at the same time, p38 MAPK may be activated as a survival mechanism to this inhibition which is susceptible to chemical inhibition.
p38 MAPK is a pharmaceutical target for inhibition in non-malignant diseases such as asthma, rheumathoid arthritis, chronic obstructive pulmonary disease or inflammatory bowel disease. 28 Earlier clinical experience with available agents suffered from target specificity limitations and off target toxicity however newer agents in clinical development may allow this to be addressed by improved target selectivity. 29 Clinical evaluation of p38 MAPK inhibition in cancer might therefore be practical and has begun, for example in myelodysplastic syndromes. 30 Our data provide a rationale now for clinical evaluation of both single agent p38 MAPK inhibition in bladder cancer and also potentially for its combination with EGFR/HER2 inhibition. Initial studies are in development. Further pre-clincial development of this approach in urothelial cancer is also warranted including with in-vivo assessment with xenograft approaches.
Conclusion
We have identified and validated p38 MAPK as a downstream signalling node that undergoes consistent phosphorylation in response to either EGFR or dual EGFR/HER2 inhibition using agents in current clinical evaluation in bladder cancer.
Inhibition of p38 MAPK led to inhibition of cell proliferation in bladder cancer models and this effect synergised with dual EGFR/HER2 inhibition. This work detects p38 MAPK as a potential therapeutic target in bladder cancer and that warrants further development. Supplementary Figure 1 ). Of these, proteins that had statistically significant changes in their phosphorylation status compared to DMSO solvent control exposed samples are indicated. 
Supplementary Figure Legends
